key: cord-0719416-7t4x9rb2
authors: Eastman, Jacqueline; Kelbel, Theodore; Holsworth, Amanda; Pebbles, Timothy; Hartog, Nicholas
title: Cohort experience of 2nd mRNA vaccine dose tolerance after an initial dose reaction
date: 2021-10-23
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.10.023
sha: eac261403e2b686881f05d1ddb0d01f055b8a7e0
doc_id: 719416
cord_uid: 7t4x9rb2

nan

Concern arose about increased rates of anaphylaxis for the two mRNA coronavirus disease 2019 (COVID-19) vaccines. [1] [2] [3] The initial concern was that history of allergy to food, medication, venom or polyethylene glycol (PEG) increased this risk, but this has not been substantiated. 3, 4 Both mRNA vaccines require two doses to achieve optimal protection against infection. 5 There is limited guidance on how to evaluate and proceed with the second dose in patients with reactions to the first. 4 Because of earlier vaccine supply issues, testing to the vaccine itself was not feasible and graded dosing protocols or testing with similar excipients was proposed. 6, 7 The validity and necessity of such testing has been questioned and refuted recently. 7, 8 This is a single-center, retrospective chart review of all patients evaluated for a possible allergic reaction to the first dose of Pfizer or Moderna COVID-19 vaccines in the allergy department of a large tertiary medical center from December 2020 through May 2021. All patients that received a vaccine within the medical system were sent a post-vaccine symptom survey. Anyone with symptoms within 4 hours that were potentially allergic were referred for further evaluation. 1 Additionally, referrals were made by primary care physicians. Patients that received a second dose after evaluation were contacted. The aim of this study is to characterize significant adverse symptoms after the first dose and outcomes of second doses. The study protocol was approved by the Spectrum Health Institutional Review Board.

A total of 72 patients were evaluated for possible reaction to either the Pfizer or Moderna vaccines. We excluded 6 patients as their symptoms were not consistent with a reaction to the vaccine based on unrelated symptoms with delayed onset. Of the 66 patients 4 included, 56 (84.8%) were female, 90% were Caucasian, and average age was 42 (range 19-69 years). Twenty-two had reported history of anaphylaxis (food or medicine) and none had history of PEG or polysorbate allergy. Fifty-three patients (80.3%) successfully received their second vaccination (48 with known symptom outcomes in Table 1 ), twelve (18.2%) refused due to patient choice (including the only person treated with epinephrine for a dose one reaction), and one (1.5%) did not receive dose two because of allergist recommendation.

Eighteen patients had hives or angioedema, with no respiratory, cardiac or gastrointestinal symptoms, after their first dose ( Table 1 ). Five of these had pre-existing chronic hives and experienced worsening following the vaccine. Nine patients with no history of urticaria experienced hives with a median onset of 1 hour later (range 15 min to 5 days) and duration 3 days (range 6 hours-60 days) after dose one. Four patients had periorbital or facial angioedema with median onset 4 hours later (range 30 min-1 day) and duration 1 day (one had duration of 7 days) after dose one. Thirteen of these patients received a second dose; only five had recurrence of symptoms with none more severe and no cases of anaphylaxis. Non-urticarial rashes were seen in five patients after dose 1, with two having delayed onset (both at 8 days) at site of injection, one with lip dermatitis (history of dermal filler use) and two with viral exanthem. Three, including the patient with lip dermatitis, received their second vaccination with no recurrence of symptoms.

Two patients had symptoms consistent with anaphylaxis (within 30 minutes, developed hives, flushing, shortness of breath, feeling of impending doom) after dose one. Neither received epinephrine. Both underwent successful desensitization procedures for their second dose (footnote d). 2 Of the patients with history of anaphylaxis unrelated to the vaccine, 18 received their second dose.

Seven of them had symptoms, with two patients having hives and five with subjective shortness of breath or itching. None required epinephrine.

Twenty-two patients had subjective symptoms including shortness of breath, palpitations, feeling warm or throat tightness after dose one; ten had a previous history of unrelated anaphylaxis. Due to the unclear etiology of the symptoms, the initial 6 patients were observed by an allergist for their second dose via either a graded vaccine challenge (10% and 90%) or direct challenge, and no patients reacted. The rest were instructed to get their second dose normally with no additional observation. Overall, 18 received their second dose. Eight (44%) had recurrence of symptoms, but all were deemed to be less severe than the initial symptoms with no resultant anaphylaxis.

Subjective neurologic complaints of dizziness, vision changes, numbness and/or tingling of mouth or extremities occurred in ten patients after dose one. Median onset was 30 minutes (range 15 minutes to 5 days) and duration 14 hours (range 45 minutes to several weeks) with all resolving. Seven received their second dose and only one had recurrence of symptoms. One patient with history of COVID-19 infection causing loss of smell and taste had symptoms recur after the initial Pfizer vaccine; it was recommended this patient not receive a second dose. One patient with history of hyperemesis gravidarum had recurrence of repetitive vomiting the day of the first dose but no recurrence with the second.

All 51 patients (77.3%) tolerated the second dose and none had what would be considered dose-limiting symptoms that would preclude future vaccine administration. No severe reactions or new cases of anaphylaxis were observed. Patients with nonanaphylactic reactions after dose one, but with symptoms concerning for IgE-mediated reactions including hives and angioedema, 6 successfully received their second dose without preceding skin testing for risk stratification. The two with anaphylaxis tolerated their second dose with a graded dose protocol. Neurologic and gastrointestinal symptoms were also mild and temporary. Our experience does not support extensive skin testing to aid in the decision to give a second dose to patients with mild to moderate symptoms, similar to what others have found. [8] [9] [10] The mechanisms of these reactions are unknown, although immediate reactions may be related to non-IgE mediated mechanisms, whereas delayed may be due to the vaccine-induced immune response. This presents an opportunity for shared decision making when discussing a second dose of mRNA vaccine in a patient who had a reaction to the first dose. 

Centers for Disease Control and Prevention Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine

Potential mechanisms of anaphylaxis to COVID-19 mRNA Vaccines

The risk of allergic reaction not SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach

Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) variant

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

Administration of a second dose of the Moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing

PEG/Polysorbate skin testing has no utility in the assessment of suspected allergic reactions to SARS-CoV-2 vaccines

Misdiagnosis of systemic allergic reaction to mRNA COVID-19 vaccines

a Patients were contacted after their second dose to assess recurrence of symptoms. Those that responded are summarized here. None developed a different type of symptom. None had anaphylaxis. b Four pre-treated with antihistamines. c Both patients developed hives, flushing, shortness of breath, feeling of impending doom within 30 minutes. d 6 step graded dose protocol with Pfizer vaccine (0.003 mL, 0.009 mL, 0.018 mL, 0.04 mL, 0.08 mL, 0.15 mL; final volume 0.3 mL) 10 e Five additional patients received the vaccine but could not be reached; recurrence of symptoms is unknown.